Sunshine Biopharma Reports 3,600% Increase in Revenue in Q2 2023 Financial Results

Sunshine Biopharma Inc. (Nasdaq: SBFM) has filed its quarterly financial results for Q2 2023, reporting a 3,600% increase in gross revenues for the period.

Dr. Steve Slilaty, CEO of Sunshine Biopharma, said, “We are thrilled with our second quarter revenue results and look forward to continued quarter over quarter growth for the rest of 2023 and beyond.”


Sunshine reported gross revenues of $5,560,865 for the quarter ended June 30, 2023, an increase of 3,600% over the same period in 2022.

The increase was largely due to the prescription drugs sales of Nora Pharma Inc., a generic pharmaceuticals company acquired by Sunshine Biopharma in 2022.

The company reported second quarter revenues of $5,560,865 represent a 13.6% increase over first quarter results.

Sunshine Biopharma offers and researches life-saving medicines in a variety of therapeutic areas including oncology and antivirals.

About Sunshine Biopharma

Sunshine Biopharma recently acquired Nora Pharma Inc. and as a result the Company now has 50 generic prescription drugs on the market in Canada and 41 additional employees. The Company is planning to expand its product offering to 77 generic prescription drugs over the next 18 months. In parallel, Sunshine Biopharma is continuing its proprietary drug development program which is comprised of (i) K1.1 mRNA for liver cancer, (ii) Adva-27a, a small chemotherapy molecule for pancreatic cancer, and (iii) PLpro protease inhibitor for COVID-19. For more information, please visit:

Share This Article


About the Author

Sunshine Biopharma Reports 3,600% Increase in Revenue in Q2 2023 Financial Results

Editor Prism MarketView